ESR1 and breast cancer: Compounds 38 and 39 (Figure 8) stood out for their potent antiproliferative activity against ER-α-positive T-47D breast cancer cells, with IC50 values of 3.24 μM and 1.72 μM, respectively, compared to the standard drug bazedoxifene (IC50 = 12.78 μM).